CDKN2A and cancer: Next, CDKN2A DEL was not related to OS in either primary or metastasis cancers (Fig. 3G and H; HR, 1.23; 95% CI, 0.55–2.77; metastasis, HR, 1.20; 95% CI, 0.38–3.74).